Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Prevalence and Risk Factors of Moderate-to-Severe Hepatic Steatosis in Human Immunodeficiency Virus Infection: The Copenhagen Co-Morbidity Liver Study

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Pulmonary Arterial Enlargement in Well-Treated Persons With Human Immunodeficiency Virus

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Interstitial lung abnormalities in people with HIV infection and uninfected controls

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Genome-wide association study of high-sensitivity C-reactive protein, D-dimer and Interleukin-6 levels in multi-ethnic HIV+ cohorts

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Switching from Vitamin K Antagonist to Dabigatran in Atrial Fibrillation: Differences According to Dose

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Vitamin K antagonists vs. direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillation

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Pulmonary Arterial Enlargement in Well-Treated Persons With Human Immunodeficiency Virus

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: People with human immunodeficiency virus (PWH) may be at risk of nonalcoholic fatty liver disease. We compared the prevalence of moderate-to-severe hepatic steatosis (M-HS) in PWH with human immunodeficiency virus (HIV)-uninfected controls and determined risk factors for M-HS in PWH. METHODS: The Copenhagen Co-Morbidity in HIV Infection study included 453 participants, and the Copenhagen General Population Study included 765 participants. None had prior or current viral hepatitis or excessive alcohol intake. Moderate-to-severe hepatic steatosis was assessed by unenhanced computed tomography liver scan defined by liver attenuation ≤48 Hounsfield units. Adjusted odds ratios (aORs) were computed by adjusted logistic regression. RESULTS: The prevalence of M-HS was lower in PWH compared with uninfected controls (8.6% vs 14.2%, P < .01). In multivariable analyses, HIV (aOR, 0.44; P < .01), female sex (aOR, 0.08; P = .03), physical activity level (aOR, 0.09; very active vs inactive; P < .01), and alcohol (aOR, 0.89 per unit/week; P = .02) were protective factors, whereas body mass index (BMI) (aOR, 1.58 per 1 kg/m2; P < .01), alanine transaminase (ALT) (aOR, 1.76 per 10 U/L; P < .01), and exposure to integrase inhibitors (aOR, 1.28 per year; P = .02) were associated with higher odds of M-HS. CONCLUSIONS: Moderate-to-severe hepatic steatosis is less common in PWH compared with demographically comparable uninfected controls. Besides BMI and ALT, integrase inhibitor exposure was associated with higher prevalence of steatosis in PWH.

Original languageEnglish
JournalThe Journal of infectious diseases
Volume222
Issue number8
Pages (from-to)1353-1362
Number of pages10
ISSN0022-1899
DOIs
Publication statusPublished - 14 Sep 2020

    Research areas

  • comorbidity, fatty liver disease, human immunodeficiency virus, NAFL, NAFLD

ID: 59857094